ASX Announcements

Dec 2016
Dec 22nd, 2016
Starpharma receives $3.5M R&D tax incentive refund
Dec 5th, 2016
Change in Director's Interest Notice - R Thomas
Dec 5th, 2016
Appendix 3B
Dec 5th, 2016
Change in Director's Interest Notice - J Fairley

Nov 2016
Nov 29th, 2016
2016 AGM Results
Nov 28th, 2016
Starpharma signs license for VivaGel Condom in Iran
Nov 8th, 2016
Starpharma to present at Bio-Europe® conference

Oct 2016
Oct 28th, 2016
Appendix 4C - Quarterly Cashflow Report
Oct 28th, 2016
Additional Priostar Glyphosate Patent Allowed in US
Oct 26th, 2016
Notice of Annual General Meeting and Proxy Form
Oct 26th, 2016
Starpharma to present at US Drug Delivery Conference
Oct 25th, 2016
Starpharma to present at ASX Spotlight in Asia
Oct 17th, 2016
Change in Director's Interest Notice - R Thomas
Oct 13th, 2016
Enrolment complete for Phase 3 VivaGel BV-R program
Oct 13th, 2016
Appendix 3B
Oct 13th, 2016
Change in Director's Interest Notice - J Fairley
Oct 7th, 2016
Change in Director's Interest Notice - J Fairley
Oct 7th, 2016
Appendix 3B
Oct 3rd, 2016
Notification of AGM date

Sep 2016
Sep 19th, 2016
Change in Director's Interest Notice - R Thomas
Sep 14th, 2016
Change in substantial holding
Sep 13th, 2016
VivaGel® condom receives regulatory approval in Canada

Aug 2016
Aug 31st, 2016
Appendix 4E - Correction to NTA Backing
Aug 30th, 2016
Starpharma Highlights of FY2016 Presentation
Aug 29th, 2016
Appendix 4G - Corporate Governance Statement
Aug 29th, 2016
Annual report and full year financial results

Jul 2016
Jul 28th, 2016
Starpharma initiates new DEP™ drug delivery program with AstraZeneca
Jul 21st, 2016
Starpharma signs license for a VivaGel® condom in China
Jul 13th, 2016
Appendix 4C - Quarterly Cashflow Report

Jun 2016
Jun 14th, 2016
Change in substantial holding

May 2016
May 25th, 2016
Starpharma's DEP eliminates cabazitaxel neutropenia
May 19th, 2016
Change in Director's Interest Notice - R Thomas
May 17th, 2016
Starpharma to present at ASX CEO Session
May 16th, 2016
Australian Olympic Team taking Dual Protect™ VivaGel® Condoms to Rio
May 5th, 2016
VivaGel active against Zika virus

Apr 2016
Apr 28th, 2016
Appendix 4C - Quarterly Cashflow Report
Apr 13th, 2016
Shareholder Update April 2016
Apr 5th, 2016
Starpharma to present at Bio-Europe conference
Apr 4th, 2016
DEP cabazitaxel shows complete and sustained tumour regression

Mar 2016
Mar 17th, 2016
Adama Licenses Starpharma's Priostar for Novel 2,4-D
Mar 4th, 2016
Starpharma licences VivaGel BV to Aspen for ANZ

Feb 2016
Feb 24th, 2016
Change in substantial holding
Feb 17th, 2016
Interim Report and Half-Year Financial Results
Feb 2nd, 2016
Targeted DEP shows sustained superior performance

Jan 2016
Jan 28th, 2016
Appendix 4C - Quarterly Cashflow Report
Jan 27th, 2016
Change in Director's Interest Notice - R Thomas
Jan 27th, 2016
Change in Director's Interest Notice - J Fairley
Jan 27th, 2016
Change in Director's Interest Notice - P Turvey
Jan 27th, 2016
Change in Director's Interest Notice - Z Peach
Jan 25th, 2016
Appendix 3B
Jan 22nd, 2016
Appendix 3B - SPP
Jan 20th, 2016
Starpharma raises $1.9M under Share Purchase Plan